



[12] Patent


<p>[11] Patent No.: GC 0000102</p> <p>[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005</p>	<p>Number of the Decision to Grant the Patent: 5/208</p> <p>Date of the Decision to Grant the Patent: 15/03/2005</p>
<p>[21] Application No.: GCC/P/1999/159</p> <p>[22] Filing Date: 19/05/1999</p> <p>[30] Priority:</p> <p>[31] Priority No. [32] Priority date [33] State 60/086,560 21/05/1998 US</p> <p>[72] Inventor: Randall K. Johnson</p> <p>[73] Owner: SmithKline Beecham Corporation, One Franklin Plaza, Philadelphia, Pennsylvania 19103, USA</p> <p>[74] Agent: Suleiman Ibrahim Al-Ammar</p>	<p>[51] Int.Cl.⁷: A61K 38/20, 31/535</p> <p>[56] Cited Documents: - EP 0767178 A1 (KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO) 09 April 1997 - WO 92/14469 A1 (SMITHKLINE BEECHAM CORPORATION) 03 September 1992</p>

[54] NOVEL COMPOSITIONS COMPRISING POTENTIATORS AND CHEMOTHERAPEUTIC AGENTS

[57] Abstract: The present invention relates generally to compositions comprising potentiators, such as IL-18, also known as interferon- γ -inducing factor (IGIF), in combination with a chemotherapeutic agent, processes for making such compositions, the use of such compositions for the prevention and/or treatment of cancer, and the use of such compositions to inhibit the growth of tumors or cancerous cells in mammals.

No. of claims: 11

No. of figures: 23



Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.